LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

LLY

1,011.28

-2.39%↓

JNJ

202.37

-1.51%↓

ABBV

228.23

-0.06%↓

UNH

334.44

-0.4%↓

AZN

90.21

-0.67%↓

Search

Simulations Plus Inc

Open

BrancheGesundheitswesen

20.68 3.82

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.83

Max

20.74

Schlüsselkennzahlen

By Trading Economics

Einkommen

-70M

-67M

Verkäufe

-2.1M

20M

KGV

Branchendurchschnitt

48.528

80.03

Dividendenrendite

0.48

Gewinnspanne

-330.585

Angestellte

243

EBITDA

327K

5.3M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+0.74% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.48%

2.29%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-7M

344M

Vorheriger Eröffnungskurs

16.86

Vorheriger Schlusskurs

20.68

Nachrichtenstimmung

By Acuity

56%

44%

310 / 374 Ranking in Healthcare

Simulations Plus Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Dez. 2025, 23:21 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3. Dez. 2025, 23:14 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3. Dez. 2025, 22:01 UTC

Wichtige Markttreiber

Costco Wholesale Reports Higher Monthly Sales

3. Dez. 2025, 21:38 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3. Dez. 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3. Dez. 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3. Dez. 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3. Dez. 2025, 23:10 UTC

Ergebnisse

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3. Dez. 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3. Dez. 2025, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3. Dez. 2025, 22:59 UTC

Akquisitionen, Fusionen, Übernahmen

EQB to Buy PC Financial From Loblaw for About $573.5M

3. Dez. 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3. Dez. 2025, 22:20 UTC

Ergebnisse

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3. Dez. 2025, 22:19 UTC

Ergebnisse

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3. Dez. 2025, 22:17 UTC

Ergebnisse

Salesforce Working to Add Voice to Agentforce, CEO Says

3. Dez. 2025, 22:16 UTC

Ergebnisse

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3. Dez. 2025, 22:15 UTC

Ergebnisse

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3. Dez. 2025, 22:10 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3. Dez. 2025, 22:09 UTC

Akquisitionen, Fusionen, Übernahmen

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3. Dez. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Dez. 2025, 21:49 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:23 UTC

Ergebnisse

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3. Dez. 2025, 21:19 UTC

Ergebnisse

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:06 UTC

Ergebnisse

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3. Dez. 2025, 21:04 UTC

Ergebnisse

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3. Dez. 2025, 21:03 UTC

Ergebnisse

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer-Vergleich

Kursveränderung

Simulations Plus Inc Prognose

Kursziel

By TipRanks

0.74% Vorteil

12-Monats-Prognose

Durchschnitt 20.5 USD  0.74%

Hoch 25 USD

Tief 16 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Simulations Plus Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

5 ratings

3

Buy

2

Halten

0

Sell

Stimmung

By Acuity

310 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat